A Low-FODMAP diet enhances IBS symptom relief and gut microbiota homeostasis: A meta-analysis

IF 4.8 1区农林科学 Q1 FOOD SCIENCE & TECHNOLOGY

Food Bioscience Pub Date : 2025-07-05 DOI:10.1016/j.fbio.2025.107190

Wanyu Yang, Huizi Tan, Shaoping Nie

{"title":"A Low-FODMAP diet enhances IBS symptom relief and gut microbiota homeostasis: A meta-analysis","authors":"Wanyu Yang, Huizi Tan, Shaoping Nie","doi":"10.1016/j.fbio.2025.107190","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder worldwide. The low-FODMAP diet (LFD), which restricts fermentable oligo-, di- and monosaccharides and polyols, has demonstrated potential efficacy in alleviating symptoms; however, current evidence remains conflicting. This study aims to integrate randomized controlled trials (RCTs) assessing LFD's impact on IBS through meta-analysis, thereby establishing a scientific foundation for clinical management.</div></div><div><h3>Methods</h3><div>We conducted a systematic literature review using databases including PubMed, Cochrane Library, Web of Science, Google Scholar, Medline, and Scopus (up to June 2024) to evaluate LFD's effects on global symptoms, gut microbiome, and related outcomes in IBS patients. Outcome data were expressed as standardized mean differences (SMD) and mean differences (MD). Quantitative synthesis was performed using random-effects or fixed-effect models.</div></div><div><h3>Result</h3><div>Ten RCTs were encompassed in this study. In comparison with the control diets (such as the traditional diet and high FODMAPs diet), the LFD resulted in significant symptom relief (IBS-SSS score: <em>n</em> = 286; <em>p</em> = 0.002; MD = −44.99, 95 % CI -74.05 to −15.91, <em>I</em><sup><em>2</em></sup> = 54 %), a higher response rate, and a notable enhancement in quality of life. Abdominal pain severity manifested significant improvement. Regarding bowel habits, the frequency of defecation decreased conspicuously, and patient satisfaction with defecation habits increased.</div></div><div><h3>Conclusion</h3><div>LFD effectively mitigates gastrointestinal symptoms and improves quality of life in IBS patients versus control diets. Further investigations should evaluate long-term effects on nutritional status and gut microbiota.</div></div>","PeriodicalId":12409,"journal":{"name":"Food Bioscience","volume":"71 ","pages":"Article 107190"},"PeriodicalIF":4.8000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food Bioscience","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212429225013677","RegionNum":1,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder worldwide. The low-FODMAP diet (LFD), which restricts fermentable oligo-, di- and monosaccharides and polyols, has demonstrated potential efficacy in alleviating symptoms; however, current evidence remains conflicting. This study aims to integrate randomized controlled trials (RCTs) assessing LFD's impact on IBS through meta-analysis, thereby establishing a scientific foundation for clinical management.

Methods

We conducted a systematic literature review using databases including PubMed, Cochrane Library, Web of Science, Google Scholar, Medline, and Scopus (up to June 2024) to evaluate LFD's effects on global symptoms, gut microbiome, and related outcomes in IBS patients. Outcome data were expressed as standardized mean differences (SMD) and mean differences (MD). Quantitative synthesis was performed using random-effects or fixed-effect models.

Result

Ten RCTs were encompassed in this study. In comparison with the control diets (such as the traditional diet and high FODMAPs diet), the LFD resulted in significant symptom relief (IBS-SSS score: n = 286; p = 0.002; MD = −44.99, 95 % CI -74.05 to −15.91, I² = 54 %), a higher response rate, and a notable enhancement in quality of life. Abdominal pain severity manifested significant improvement. Regarding bowel habits, the frequency of defecation decreased conspicuously, and patient satisfaction with defecation habits increased.

Conclusion

LFD effectively mitigates gastrointestinal symptoms and improves quality of life in IBS patients versus control diets. Further investigations should evaluate long-term effects on nutritional status and gut microbiota.

查看原文本刊更多论文

低fodmap饮食促进IBS症状缓解和肠道微生物群稳态：一项荟萃分析

背景肠易激综合征（IBS）是世界范围内普遍存在的一种胃肠道疾病。低fodmap饮食（LFD）限制可发酵的寡糖、双糖、单糖和多元醇，已经证明了缓解症状的潜在功效；然而，目前的证据仍然相互矛盾。本研究旨在整合随机对照试验（RCTs），通过meta分析评估LFD对IBS的影响，从而为临床管理奠定科学基础。方法利用PubMed、Cochrane Library、Web of Science、谷歌Scholar、Medline和Scopus等数据库（截止到2024年6月）进行系统文献综述，评估LFD对IBS患者整体症状、肠道微生物组和相关结局的影响。结果数据以标准化平均差异（SMD）和平均差异（MD）表示。采用随机效应或固定效应模型进行定量综合。结果本研究纳入了10项随机对照试验。与对照饮食（如传统饮食和高FODMAPs饮食）相比，LFD显著缓解了症状(IBS-SSS评分：n = 286；p = 0.002；MD = - 44.99, 95% CI = -74.05 ~ - 15.91, I2 = 54%)，有效率更高，生活质量显著提高。腹痛严重程度有明显改善。排便习惯方面，排便次数明显减少，患者对排便习惯的满意度提高。结论与对照饮食相比，低脂饮食可有效缓解IBS患者的胃肠道症状，提高患者的生活质量。进一步的研究应评估对营养状况和肠道微生物群的长期影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Food Bioscience Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

6.40

自引率

5.80%

发文量

671

审稿时长

27 days

期刊介绍： Food Bioscience is a peer-reviewed journal that aims to provide a forum for recent developments in the field of bio-related food research. The journal focuses on both fundamental and applied research worldwide, with special attention to ethnic and cultural aspects of food bioresearch.